ENDOPROTECH, INC.

Company Information
Address 1044 E CHESTNUT ST
LOUISVILLE, KY, 40204-1019


Information

DUNS: 144667602

# of Employees: N/A


Ownership Information

HUBZone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. A Novel Lipotherapy to Reduce Infarct Size Following Myocardial Infarction

    Amount: $224,812.00

    DESCRIPTION provided by applicant According to the CDC in ischemic heart disease is the leading cause of death worldwide and in the US approximately patients died of ischemic heart d ...

    SBIRPhase I2016Department of Health and Human Services
  2. Novel Drug Carrier System for the Treatment of Alcoholic Liver Disease

    Amount: $1,414,341.00

    DESCRIPTION provided by applicant Alcoholic Liver Disease ALD remains a leading cause of death from liver disease in the U S and no FDA approved therapy exists Abnormal cytokine metabolism is ...

    SBIRPhase II2015Department of Health and Human Services
  3. Device for Delivery of Rolipram to Liver for Treatment of Alcoholic Liver Disease

    Amount: $277,707.00

    DESCRIPTION (provided by applicant): Alcoholic Liver Disease (ALD) remains a leading cause of death from liver disease in the U.S., and there is still no FDA-approved therapy. Abnormal cytokine metabo ...

    SBIRPhase I2012Department of Health and Human Services
  4. New anti-complement therapy to reduce reperfusion injury: Phase II

    Amount: $963,666.00

    DESCRIPTION (provided by applicant): Tissue and organ transplantation procedures save and/or improve the lives of hundred of thousands of patients annually in the US. The goal of this research is to d ...

    STTRPhase II2008Department of Health and Human Services
  5. New anti-complement therapy to reduce reperfusion injury

    Amount: $122,978.00

    DESCRIPTION (provided by applicant): The purpose of this proposal is to provide proof-of-concept that a novel therapy that prevents complement activation could be effective in reducing ischemia rep ...

    STTRPhase I2005Department of Health and Human Services
  6. New anti-complement therapy to reduce reperfusion injury

    Amount: $122,978.00

    DESCRIPTION (provided by applicant): The purpose of this proposal is to provide proof-of-concept that a novel therapy that prevents complement activation could be effective in reducing ischemia rep ...

    SBIRPhase IDepartment of Health and Human Services

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government